ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2021
Evolution of
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pertactin deficiency ofHuman vaccines & immunotherapeutics · 2024Pooled it
- Global phylogenomics of Bordetella pertussis ST2 reveals regional heterogeneity in China and lineage-specific genome evolution.BMC genomics · 2026Article
- The evolution of pertactin expression in Belgian circulatingMicrobiology spectrum · 2026Article
- Genomic surveillance reveals global spread of macrolide-resistantJournal of clinical microbiology · 2025Article
- No innocent bystanders: pertussis vaccination and evolutionary parallelisms betweenMicrobial genomics · 2025Article
- Article
- Resurgence ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Bordetella spp. block eosinophil recruitment to suppress the generation of early mucosal protection.Cell reports · 2023Article
- Review
- Fim3-dependent autoagglutination of Bordetella pertussis.Scientific reports · 2023Article
- A comprehensive resource for Bordetella genomic epidemiology and biodiversity studies.Nature communications · 2022Article
- Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.Emerging infectious diseases · 2022Article
- Non-primate animal models for pertussis: back to the drawing board?Applied microbiology and biotechnology · 2022Review
- A Cross-Sectional Study Revealing the Emergence of Erythromycin-ResistantFrontiers in microbiology · 2022Article
- Can vaccines control bacterial virulence and pathogenicity?Evolution, medicine, and public health · 2022Review
- Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity AgainstFrontiers in immunology · 2022Article
- Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.